VRK1 as a synthetic lethal target in VRK2 promoter–methylated cancers of the nervous system

• DOI: 10.1172/jci.insight.158755
• Publication Date: 2022-08-30T16:01:29Z
• Authors: Jonathan So; Nathaniel W. Mabe; Bernhard Englinger; Kin-Hoe Chow; Sydney M. Moyer; Smitha Yerrum; Maria C. Trissal; Joana G. Marques; Jason J. Kwon; Brian Shim; Sangita Pal; Eshini Panditharatna; Thomas Quinn; Daniel A. Schaefer; Daeun Jeong; David L. Mayhew; Justin Hwang; Rameen Beroukhim; Keith L. Ligon; Kimberly Stegmaier; Mariella G. Filbin; William C. Hahn
• Keywords: 0303 health sciences; R; Intracellular Signaling Peptides and Proteins; Vaccinia virus; Glioma; Protein Serine-Threonine Kinases; Nervous System; 3. Good health; Neuroblastoma; 03 medical and health sciences; Oncology; Vaccinia; Medicine; Humans; Child; Research Article

Collateral lethality occurs when loss of a gene/protein renders cancer cells dependent on its remaining paralog. Combining genome-scale CRISPR/Cas9 loss-of-function screens with RNA sequencing in over 900 cancer cell lines, we found that cancers of nervous system lineage, including adult and pediatric gliomas and neuroblastomas, required the nuclear kinase vaccinia-related kinase 1 (VRK1) for their survival in vivo. VRK1 dependency was inversely correlated with expression of its paralog VRK2. VRK2 knockout sensitized cells to VRK1 loss, and conversely, VRK2 overexpression increased cell fitness in the setting of VRK1 loss. DNA methylation of the VRK2 promoter was associated with low VRK2 expression in human neuroblastomas and adult and pediatric gliomas. Mechanistically, depletion of VRK1 reduced barrier-to-autointegration factor phosphorylation during mitosis, resulting in DNA damage and apoptosis. Together, these studies identify VRK1 as a synthetic lethal target in VRK2 promoter-methylated adult and pediatric gliomas and neuroblastomas.